Results from the Phase II study of NP001, a drug targeting inflammation caused by immune cells called microglia, demonstrated a non-statistically significant slowing of disease progression by 13-19%.
However, extended analysis revealed that a subset of individuals taking NP001 experienced a complete arrest in disease progression compared to placebo controls over a six month period. NP001 was also found to be safe without any significant adverse events. These results have led Neuraltus to plan a Phase III trial for the second half of 2013.
For more information please visit: